In a research report to clients Tuesday, Atkinson initiated coverage of StageZero with a “Speculative Buy” rating and a one-year price target of $0.50, implying a return of 823 per cent at the time of publication.
The analyst explained the company’s offering and its opportunity,
“StageZero Life Sciences Inc., is a molecular diagnostic company focused on early cancer detection throughout a person’s body. It is a radical step forward, offering simple, genomic-based screening for some of the most common and lethal cancer types and able to identify even early-stage 1 cancers,” Atkinson noted. “Public and private comparables carry multi-billion-dollar valuations. StageZero’s proprietary Aristotle liquid biopsy diagnostic panel is expansive (10 types of cancer can be identified) and showed solid performance metrics in a large trial. We expect Aristotle to launch in the U.S., Canada and Europe by Q1/21 – and in the meantime StageZero is generating revenues from Covid testing services at its Virginia lab.”
Atkinson also explained the reason why investors will not be faced with the long waits typical to life sciences stocks.
“We believe StageZero’s proprietary Aristotle platform is positioned to become a leading liquid biopsy solution,” he argued. “It can identify ten different types of cancer from a single blood test and catch cancer at even the earliest stages. Unlike drugs, most diagnostic tests do not need regulatory approval before commercial launch, and we expect Aristotle revenues to begin in the U.S., Canada, and Europe by
Q1/21. Aristotle could be the first commercially-available multi-cancer liquid biopsy product, and we expect rapid revenue growth during our forecast period ending 2022. The peer group of liquid biopsy companies trades at a very substantial price/sales multiple, so if Aristotle can achieve market acceptance, we expect StageZero’s share price to rise significantly from current levels.”
Ahead of the company's fourth quarter earnings report, due May 16, Stifel analyst Justin Keywood says ATS Corp (ATS Corp… [Read More]
Its first quarter results are in the books and Roth MKM analyst Justin Clare thinks there is money to be… [Read More]
Beacon analyst Russell Stanley says the most recent results were better than expected for The Cannabist Company (The Cannabist Company… [Read More]
Following the company's first quarter results, National Bank Financial analyst Richard Tse has maintained his "Outperform" rating on Constellation Software… [Read More]
Its first quarter results are in the books and National Bank Financials analyst Richard Tse is feeling less bullish about… [Read More]
Following the company's first quarter results, Echelon Capital Markets analyst Andrew Semple has maintained his "Hold" rating on Jushi Holdings… [Read More]